Erica L. Mayer, MD, MPH

In this video, Erica Mayer, MD, MPH, from Dana-Farber Cancer Institute in Boston, MA, reviews results from the EMBER-3 trial exploring imlunestrant, with and without abemaciclib, as a novel, all-oral, chemotherapy-free therapy in the treatment of patients with estrogen receptor–positive/HER2-negative breast cancer. Read More ›

Dr Erica Mayer explains the results of a study utilizing the novel SERD SIM0270, as monotherapy and in combination, in the treatment of patients with estrogen receptor–positive, HER2-negative advanced breast cancer. Read More ›

Dr Erica Mayer discusses an analysis of the EMERALD study, which explores the effects of variant allele frequencies on outcomes for patients with advanced breast cancer being treated with elacestrant. Read More ›

Dr Erica Mayer comments on real-world outcomes for elacestrant derived from the GuardantINFORM database, and describes which patients elacestrant therapy may be best for. Read More ›

Dr Erica Mayer discusses the positive results of the EMBER-3 trial, and the impact that imlunestrant will have on the treatment of patients with advanced breast cancer Read More ›